Home / Market News / $VRTX
benzinga Corporate Catalyst Impact 55/100 ● positive

UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615

Sep 28, 2026, 6:00 PM UTC · Primary ticker $VRTX

UBS analyst Michael Yee reiterated a 'Buy' rating on Vertex Pharmaceuticals and increased the price target from $585 to $615. This indicates continued analyst confidence in the company's future performance, which could lead to a modest positive sentiment for the stock.

UBS analyst Michael Yee maintained a 'Buy' rating on Vertex Pharmaceuticals (VRTX) and raised the price target from $585 to $615. This action signals continued bullish sentiment from a prominent investment bank regarding VRTX's prospects. For traders, this could provide a short-term positive bump as the market reacts to the increased price target, potentially attracting new investors or reinforcing existing positions. Long-term implications depend on whether the company's fundamentals align with this optimistic outlook, but it generally supports a positive investment thesis. The key opportunity for traders is to capitalize on any immediate upward momentum driven by this analyst upgrade.

$VRTX positive Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.